BiotechTube
EsoCap

EsoCap

Basel, Switzerland· Est.
esocapbiotech.ch
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $40.5M

Overview

EsoCap is a clinical-stage biotech company pioneering a novel drug delivery platform for esophageal diseases. Its core innovation is a mucoadhesive film technology that allows therapeutic agents to adhere to the esophageal wall for extended periods, enabling effective local treatment. The company's lead candidate, ESO-101 for eosinophilic esophagitis (EoE), has successfully completed a Phase II trial and holds FDA Orphan Drug Designation. EsoCap is leveraging its versatile platform to develop treatments for other conditions like reflux disease, Barrett's esophagus, and esophageal cancer.

GastroenterologyImmunology

Technology Platform

Proprietary mucoadhesive film-based drug delivery system designed to adhere to the esophageal wall, significantly increasing drug contact time and enabling localized treatment of esophageal diseases. Compatible with small molecules, peptides, antibodies, and liposomal RNA.

Funding History

2
Total raised:$40.5M
Series A$35M
Seed$5.5M

Opportunities

The successful Phase II validation of its platform creates a significant opportunity to advance ESO-101 in the growing EoE market and to out-license or partner the technology for broader applications.
The platform's compatibility with diverse drug classes, including RNA therapeutics, opens avenues in larger markets like GERD, Barrett's esophagus, and esophageal cancer.

Risk Factors

Key risks include the need for successful and costly Phase III trials, potential challenges in patient adoption of a novel delivery system, and intense competition in the GI therapeutic space from larger companies with greater resources.
As a pre-revenue private company, securing sufficient funding for late-stage development is also a critical risk.

Competitive Landscape

EsoCap competes in the EoE space with swallowed steroid slurries, upcoming biologics, and other drug delivery approaches. Its primary differentiation is its dedicated, validated platform for prolonged esophageal contact. For broader indications, it faces competition from systemic therapies and other localized delivery devices, but its film-based technology offers a unique mechanism of action.

More companies in Drug Delivery & Formulation →More companies in Switzerland →